valproic acid has been researched along with Fatty Liver in 40 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Fatty Liver: Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Both high fat diet (HFD) and valproic acid (VPA) interfere with mitochondrial β-oxidation of fatty acids, which subsequently triggers microvesicular fatty liver and hepatic dysfunction." | 7.79 | Dysregulations of UDP-glucuronosyltransferases in rats with valproic acid and high fat diet induced fatty liver. ( Cao, L; Chu, X; Guo, C; Hao, H; Wang, G; Wang, H; Xie, H; Zhang, L; Zhou, X, 2013) |
| "Valproic acid (VPA), as one of the most widely prescribed antiepileptic drugs (AED) for many types of epilepsy in adults and children, is associated with weight gain, alteration of adipocytokine homeostasis, insulin resistance and Non-Alcoholic Fatty Liver Disease (NAFLD)." | 7.79 | The novel insulin resistance parameters RBP4 and GLP-1 in patients treated with valproic acid: just a sidestep? ( Ebenbichler, CF; Laimer, M; Luef, G; Rauchenzauner, M; Salzmann, K; Sandhofer, A; Sturm, W; Tschoner, A; Walser, G; Wiedmann, M, 2013) |
| "Patients treated with valproic acid (VPA) present a high incidence of non-alcoholic fatty liver disease (NAFLD) (around 61%)." | 7.77 | A preliminary investigation on the possible association between diminished copper availability and non-alcoholic fatty liver disease in epileptic patients treated with valproic acid. ( Lampon, N; Tutor, JC, 2011) |
| " He had been obese, had been receiving a standard dose of valproic acid since clipping surgery for subarachnoid hemorrhage 17 years previously, and had not consumed any alcohol since the surgery." | 7.73 | Hepatocellular carcinoma and nonalcoholic steatohepatitis developing during long-term administration of valproic acid. ( Iizuka, H; Katsuda, S; Okamoto, K; Sato, K; Ueda, Y; Ueno, K, 2005) |
| "Valproic acid (VPA) has been used as anticonvulsants, however, it induces hepatotoxicity such as microvesicular steatosis and necrosis in the liver." | 5.34 | Gene expression profiles of murine fatty liver induced by the administration of valproic acid. ( Chung, H; Hong, I; Kang, KS; Kim, HL; Kim, JH; Kim, M; Kong, G; Lee, BH; Lee, MH; Lee, MO; Yoon, BI, 2007) |
| "We present the case of a 47-year-old man who had bipolar disorder for ten years and treated with valproic acid." | 3.83 | Valproic Acid and Hepatic Steatosis: A Possible Link? About a Case Report. ( Masmoudi, J; Mnif, L; Sellami, R, 2016) |
| "Both high fat diet (HFD) and valproic acid (VPA) interfere with mitochondrial β-oxidation of fatty acids, which subsequently triggers microvesicular fatty liver and hepatic dysfunction." | 3.79 | Dysregulations of UDP-glucuronosyltransferases in rats with valproic acid and high fat diet induced fatty liver. ( Cao, L; Chu, X; Guo, C; Hao, H; Wang, G; Wang, H; Xie, H; Zhang, L; Zhou, X, 2013) |
| "Valproic acid (VPA), as one of the most widely prescribed antiepileptic drugs (AED) for many types of epilepsy in adults and children, is associated with weight gain, alteration of adipocytokine homeostasis, insulin resistance and Non-Alcoholic Fatty Liver Disease (NAFLD)." | 3.79 | The novel insulin resistance parameters RBP4 and GLP-1 in patients treated with valproic acid: just a sidestep? ( Ebenbichler, CF; Laimer, M; Luef, G; Rauchenzauner, M; Salzmann, K; Sandhofer, A; Sturm, W; Tschoner, A; Walser, G; Wiedmann, M, 2013) |
| "Patients treated with valproic acid (VPA) present a high incidence of non-alcoholic fatty liver disease (NAFLD) (around 61%)." | 3.77 | A preliminary investigation on the possible association between diminished copper availability and non-alcoholic fatty liver disease in epileptic patients treated with valproic acid. ( Lampon, N; Tutor, JC, 2011) |
| "Valproic acid (VPA) is effective for the treatment of many types of epilepsy, but its use can be associated with an increase in body weight." | 3.75 | Nonalcoholic fatty liver disease during valproate therapy. ( Chiarelli, F; Di Marco, G; la Torre, R; Pelliccia, P; Verrotti, A, 2009) |
| " He had been obese, had been receiving a standard dose of valproic acid since clipping surgery for subarachnoid hemorrhage 17 years previously, and had not consumed any alcohol since the surgery." | 3.73 | Hepatocellular carcinoma and nonalcoholic steatohepatitis developing during long-term administration of valproic acid. ( Iizuka, H; Katsuda, S; Okamoto, K; Sato, K; Ueda, Y; Ueno, K, 2005) |
| "Drug-induced steatohepatitis is a rare form of liver injury known to be caused by only a handful of compounds." | 2.52 | Mechanistic review of drug-induced steatohepatitis. ( Guo, GL; Schumacher, JD, 2015) |
| "Valproic acid (VPA) is a frequently prescribed anti-epileptic drug which is known to cause liver toxicity and steatosis through mitochondrial dysfunction." | 1.56 | Valproic acid promotes mitochondrial dysfunction in primary human hepatocytes in vitro; impact of C/EBPα-controlled gene expression. ( Caiment, F; Kleinjans, J; Schrooders, Y; Smit, E; van den Beucken, T; Wolters, J, 2020) |
| "Valproic acid (VPA) is a very potent anti-cancer and neuro-protective drug probably by its HDAC inhibiting properties, which may cause steatosis in the liver." | 1.48 | Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. ( Claessen, SMH; de Kok, TMCM; Jennen, DGJ; Kleinjans, JCS; Theunissen, DHJ; van Breda, SGJ; van Herwijnen, M, 2018) |
| "Using pentylenetetrazole (PTZ)-induced seizures model in mice, the effect of DATS on the anticonvulsant activity of VP was found to be positive, meaning that combination of DATS with VP can confer protection against VP-induced hepatic injurious effects through its antioxidant, antiinflammatory, and antiapoptotic properties without affecting VP antiepileptic activity." | 1.46 | Cytoprotective effects of diallyl trisulfide against valproate-induced hepatotoxicity: new anticonvulsant strategy. ( El-Agamy, DS; Shaaban, AA, 2017) |
| "Valproic acid (VPA) is an anti-epileptic drug used in patients with convulsive seizures and psychic disorders." | 1.43 | High-calorie diet inflates steatogenic effects of valproic acid in mice. ( Anuradha, CV; Bhavani, K; Sathiya Priya, C, 2016) |
| "Therefore, heterozygous juvenile visceral steatosis (jvs)(+/-) mice, an animal model with decreased carnitine stores caused by impaired renal reabsorption of carnitine, and the corresponding wild-type mice were treated with subtoxic oral doses of VPA (0." | 1.35 | Toxicity of valproic acid in mice with decreased plasma and tissue carnitine stores. ( Beier, K; Knapp, AC; Krähenbühl, S; Reichen, J; Sägesser, H; Terracciano, L; Todesco, L, 2008) |
| "Valproic acid (VPA) has been used as anticonvulsants, however, it induces hepatotoxicity such as microvesicular steatosis and necrosis in the liver." | 1.34 | Gene expression profiles of murine fatty liver induced by the administration of valproic acid. ( Chung, H; Hong, I; Kang, KS; Kim, HL; Kim, JH; Kim, M; Kong, G; Lee, BH; Lee, MH; Lee, MO; Yoon, BI, 2007) |
| "Pretreatment with clofibrate results in partial reversal of changes produced by valproate." | 1.33 | Oxidative stress in experimental liver microvesicular steatosis: role of mitochondria and peroxisomes. ( Balasubramanian, KA; Eapen, CE; Natarajan, SK; Pullimood, AB, 2006) |
| "Valproic acid has been implicated in at least 100 cases of fatal acute liver failure." | 1.28 | Incidental microvesicular steatosis due to valproic acid anticonvulsant therapy. ( Bacon, BR; Gholson, CF; Gonzalez, E; Netchvolodoff, CV; Ray, M; Scott, DA, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (7.50) | 18.7374 |
| 1990's | 4 (10.00) | 18.2507 |
| 2000's | 10 (25.00) | 29.6817 |
| 2010's | 20 (50.00) | 24.3611 |
| 2020's | 3 (7.50) | 2.80 |
| Authors | Studies |
|---|---|
| Jutrić, D | 1 |
| Đikić, D | 1 |
| Boroš, A | 1 |
| Odeh, D | 1 |
| Drozdek, SD | 1 |
| Gračan, R | 1 |
| Dragičević, P | 1 |
| Crnić, I | 1 |
| Jurčević, IL | 1 |
| Gai, Z | 1 |
| Krajnc, E | 1 |
| Samodelov, SL | 1 |
| Visentin, M | 1 |
| Kullak-Ublick, GA | 1 |
| Caiment, F | 1 |
| Wolters, J | 1 |
| Smit, E | 1 |
| Schrooders, Y | 1 |
| Kleinjans, J | 1 |
| van den Beucken, T | 1 |
| Bai, X | 1 |
| Hong, W | 1 |
| Cai, P | 1 |
| Chen, Y | 1 |
| Xu, C | 1 |
| Cao, D | 1 |
| Yu, W | 1 |
| Zhao, Z | 1 |
| Huang, M | 1 |
| Jin, J | 1 |
| Shaaban, AA | 1 |
| El-Agamy, DS | 2 |
| van Breda, SGJ | 1 |
| Claessen, SMH | 1 |
| van Herwijnen, M | 1 |
| Theunissen, DHJ | 1 |
| Jennen, DGJ | 1 |
| de Kok, TMCM | 1 |
| Kleinjans, JCS | 1 |
| Goda, K | 1 |
| Saito, K | 1 |
| Muta, K | 1 |
| Kobayashi, A | 1 |
| Saito, Y | 1 |
| Sugai, S | 1 |
| Zhang, L | 1 |
| Chu, X | 1 |
| Wang, H | 1 |
| Xie, H | 1 |
| Guo, C | 1 |
| Cao, L | 1 |
| Zhou, X | 1 |
| Wang, G | 1 |
| Hao, H | 1 |
| Szalowska, E | 1 |
| van der Burg, B | 1 |
| Man, HY | 1 |
| Hendriksen, PJ | 1 |
| Peijnenburg, AA | 1 |
| Vitins, AP | 1 |
| Kienhuis, AS | 1 |
| Speksnijder, EN | 1 |
| Roodbergen, M | 1 |
| Luijten, M | 1 |
| van der Ven, LT | 1 |
| Amacher, DE | 1 |
| Chalasani, N | 1 |
| Benet, M | 1 |
| Guzmán, C | 1 |
| Pisonero-Vaquero, S | 1 |
| García-Mediavilla, MV | 1 |
| Sánchez-Campos, S | 1 |
| Martínez-Chantar, ML | 1 |
| Donato, MT | 1 |
| Castell, JV | 1 |
| Jover, R | 1 |
| Vinken, M | 1 |
| Schumacher, JD | 1 |
| Guo, GL | 1 |
| Sathiya Priya, C | 1 |
| Bhavani, K | 1 |
| Anuradha, CV | 1 |
| Chang, R | 1 |
| Chou, MC | 1 |
| Hung, LY | 1 |
| Wang, ME | 1 |
| Hsu, MC | 1 |
| Chiu, CH | 1 |
| Mnif, L | 1 |
| Sellami, R | 1 |
| Masmoudi, J | 1 |
| Bowes, AJ | 2 |
| Khan, MI | 2 |
| Shi, Y | 2 |
| Robertson, L | 1 |
| Werstuck, GH | 2 |
| Verrotti, A | 1 |
| Di Marco, G | 1 |
| la Torre, R | 1 |
| Pelliccia, P | 1 |
| Chiarelli, F | 1 |
| Aires, CC | 2 |
| Ijlst, L | 2 |
| Stet, F | 1 |
| Prip-Buus, C | 1 |
| de Almeida, IT | 1 |
| Duran, M | 2 |
| Wanders, RJ | 2 |
| Silva, MF | 2 |
| Said, SA | 1 |
| Lampon, N | 1 |
| Tutor, JC | 1 |
| McAlpine, CS | 1 |
| Elphick, LM | 1 |
| Pawolleck, N | 1 |
| Guschina, IA | 1 |
| Chaieb, L | 1 |
| Eikel, D | 1 |
| Nau, H | 1 |
| Harwood, JL | 1 |
| Plant, NJ | 1 |
| Williams, RS | 1 |
| Rauchenzauner, M | 1 |
| Laimer, M | 1 |
| Wiedmann, M | 1 |
| Tschoner, A | 1 |
| Salzmann, K | 1 |
| Sturm, W | 2 |
| Sandhofer, A | 1 |
| Walser, G | 1 |
| Luef, G | 1 |
| Ebenbichler, CF | 1 |
| Luef, GJ | 1 |
| Waldmann, M | 1 |
| Naser, A | 1 |
| Trinka, E | 1 |
| Unterberger, I | 1 |
| Bauer, G | 1 |
| Lechleitner, M | 1 |
| Tong, V | 1 |
| Teng, XW | 1 |
| Chang, TK | 1 |
| Abbott, FS | 1 |
| Sato, K | 1 |
| Ueda, Y | 1 |
| Ueno, K | 1 |
| Okamoto, K | 1 |
| Iizuka, H | 1 |
| Katsuda, S | 1 |
| Natarajan, SK | 1 |
| Eapen, CE | 1 |
| Pullimood, AB | 1 |
| Balasubramanian, KA | 1 |
| Lee, MH | 2 |
| Hong, I | 1 |
| Kim, M | 2 |
| Lee, BH | 2 |
| Kim, JH | 2 |
| Kang, KS | 2 |
| Kim, HL | 2 |
| Yoon, BI | 2 |
| Chung, H | 2 |
| Kong, G | 2 |
| Lee, MO | 2 |
| Knapp, AC | 1 |
| Todesco, L | 1 |
| Beier, K | 1 |
| Terracciano, L | 1 |
| Sägesser, H | 1 |
| Reichen, J | 1 |
| Krähenbühl, S | 1 |
| Luis, PB | 1 |
| Ruiter, JP | 1 |
| Tavares de Almeida, I | 1 |
| Kolts, BE | 1 |
| Langfitt, M | 1 |
| Ware, S | 1 |
| Millward-Sadler, GH | 1 |
| Levin, TL | 1 |
| Berdon, WE | 1 |
| Seigle, RR | 1 |
| Nash, MA | 1 |
| Baillie, J | 1 |
| Baillie, TA | 1 |
| Flueckiger, F | 1 |
| Steiner, H | 1 |
| Leitinger, G | 1 |
| Hoedl, S | 1 |
| Deu, E | 1 |
| Scott, DA | 1 |
| Gholson, CF | 1 |
| Netchvolodoff, CV | 1 |
| Ray, M | 1 |
| Gonzalez, E | 1 |
| Bacon, BR | 1 |
| Coraggio, F | 1 |
| Angiulli, B | 1 |
| Carbone, M | 1 |
| Catalano, A | 1 |
| Costa, MR | 1 |
| Gargiulo, L | 1 |
| Gentile, B | 1 |
| Masetto, O | 1 |
| Pomponio, N | 1 |
| Scarpato, P | 1 |
5 reviews available for valproic acid and Fatty Liver
| Article | Year |
|---|---|
Drug-induced hepatic steatosis.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Anti-Retroviral Agents; Anticholesteremic Agents; Antic | 2014 |
Adverse Outcome Pathways and Drug-Induced Liver Injury Testing.
Topics: Bosentan; Chemical and Drug Induced Liver Injury; Cholestasis; Fatty Liver; Humans; Liver Cirrhosis; | 2015 |
Mechanistic review of drug-induced steatohepatitis.
Topics: Amiodarone; Animals; Camptothecin; Chemical and Drug Induced Liver Injury; Disease Models, Animal; F | 2015 |
Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review.
Topics: Animals; Anticonvulsants; Biotransformation; Chemical and Drug Induced Liver Injury; Fatty Acids; Fa | 2008 |
[Acute hepatic steatosis. Description of a clinical case of sodium valproate-induced acute hepatic steatosis].
Topics: Acute Disease; Adult; Biopsy; Child; Child, Preschool; Diagnosis, Differential; Fatty Liver; Fatty L | 1988 |
35 other studies available for valproic acid and Fatty Liver
| Article | Year |
|---|---|
Effects of naringin and valproate interaction on liver steatosis and dyslipidaemia parameters in male C57BL6 mice.
Topics: Animals; Cholesterol, LDL; Dyslipidemias; Fatty Liver; Flavanones; Liver; Male; Mice; Mice, Inbred C | 2022 |
Obeticholic Acid Ameliorates Valproic Acid-Induced Hepatic Steatosis and Oxidative Stress.
Topics: Animals; Antioxidants; Body Weight; Cell Line, Tumor; Chenodeoxycholic Acid; Cytochrome P-450 Enzyme | 2020 |
Valproic acid promotes mitochondrial dysfunction in primary human hepatocytes in vitro; impact of C/EBPα-controlled gene expression.
Topics: Anticonvulsants; Biomarkers; CCAAT-Enhancer-Binding Protein-alpha; Cells, Cultured; Fatty Liver; Gen | 2020 |
Valproate induced hepatic steatosis by enhanced fatty acid uptake and triglyceride synthesis.
Topics: Animals; Diacylglycerol O-Acyltransferase; Fatty Acids; Fatty Liver; Hep G2 Cells; Humans; Mice; Mic | 2017 |
Cytoprotective effects of diallyl trisulfide against valproate-induced hepatotoxicity: new anticonvulsant strategy.
Topics: Allyl Compounds; Animals; Anti-Inflammatory Agents; Anticonvulsants; Antioxidants; Apoptosis; Chemic | 2017 |
Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction.
Topics: Adult; Cells, Cultured; DNA Methylation; Fatty Liver; Female; Gene Expression Profiling; Gene Expres | 2018 |
Ether-phosphatidylcholine characterized by consolidated plasma and liver lipidomics is a predictive biomarker for valproic acid-induced hepatic steatosis.
Topics: Animals; Anticonvulsants; Biomarkers; Fatty Liver; Humans; Lipid Metabolism; Lipids; Liver; Male; Mi | 2018 |
Dysregulations of UDP-glucuronosyltransferases in rats with valproic acid and high fat diet induced fatty liver.
Topics: Animals; Diet, High-Fat; Fatty Liver; Gene Expression Regulation, Enzymologic; Glucuronosyltransfera | 2013 |
Model steatogenic compounds (amiodarone, valproic acid, and tetracycline) alter lipid metabolism by different mechanisms in mouse liver slices.
Topics: Amiodarone; Animals; Enzyme Inhibitors; Extracellular Matrix; Fatty Liver; Gene Expression; Gene Exp | 2014 |
Mechanisms of amiodarone and valproic acid induced liver steatosis in mouse in vivo act as a template for other hepatotoxicity models.
Topics: Amiodarone; Animals; Binding Sites; Cell Line; Chemical and Drug Induced Liver Injury; Disease Model | 2014 |
Repression of the nuclear receptor small heterodimer partner by steatotic drugs and in advanced nonalcoholic fatty liver disease.
Topics: Animals; CCAAT-Enhancer-Binding Protein-alpha; Cells, Cultured; Cyclosporine; Doxycycline; Fatty Liv | 2015 |
High-calorie diet inflates steatogenic effects of valproic acid in mice.
Topics: Animals; Biomarkers; Blood Glucose; Diet, Western; Dietary Carbohydrates; Dietary Fats; Fatty Liver; | 2016 |
Study of Valproic Acid-Enhanced Hepatocyte Steatosis.
Topics: CD36 Antigens; Diacylglycerol O-Acyltransferase; Fatty Acids; Fatty Liver; Gene Expression Regulatio | 2016 |
Valproic Acid and Hepatic Steatosis: A Possible Link? About a Case Report.
Topics: Anticonvulsants; Bipolar Disorder; Fatty Liver; Humans; Male; Middle Aged; Valproic Acid | 2016 |
Valproate attenuates accelerated atherosclerosis in hyperglycemic apoE-deficient mice: evidence in support of a role for endoplasmic reticulum stress and glycogen synthase kinase-3 in lesion development and hepatic steatosis.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Blotting, Western; Cells, Cultured; Endoplasmic Reticul | 2009 |
Nonalcoholic fatty liver disease during valproate therapy.
Topics: Anticonvulsants; Body Mass Index; Child; Epilepsy; Fatty Liver; Fatty Liver, Alcoholic; Female; Huma | 2009 |
Inhibition of hepatic carnitine palmitoyl-transferase I (CPT IA) by valproyl-CoA as a possible mechanism of valproate-induced steatosis.
Topics: Acyl Coenzyme A; Animals; Anticonvulsants; Carnitine O-Palmitoyltransferase; Cells, Cultured; Enzyme | 2010 |
Prevention of sodium valproate-induced hepatotoxicity by curcumin, rosiglitazone and N-acetylcysteine in rats.
Topics: Acetylcysteine; Animals; Anticonvulsants; Body Weight; Chemical and Drug Induced Liver Injury; Convu | 2010 |
A preliminary investigation on the possible association between diminished copper availability and non-alcoholic fatty liver disease in epileptic patients treated with valproic acid.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Biological Availability; Copper; Epilep | 2011 |
Endoplasmic reticulum stress and glycogen synthase kinase-3β activation in apolipoprotein E-deficient mouse models of accelerated atherosclerosis.
Topics: Animals; Aorta; Apolipoproteins E; Atherosclerosis; Diet, High-Fat; Disease Models, Animal; Endoplas | 2012 |
Conserved valproic-acid-induced lipid droplet formation in Dictyostelium and human hepatocytes identifies structurally active compounds.
Topics: Cell Line; Dictyostelium; Fatty Acids; Fatty Liver; Hepatocytes; Humans; Inositol; Kinetics; Lipid M | 2012 |
The novel insulin resistance parameters RBP4 and GLP-1 in patients treated with valproic acid: just a sidestep?
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Diabetes Mellitus, Type 2; Fatty Liver; Female; Glu | 2013 |
Valproate therapy and nonalcoholic fatty liver disease.
Topics: Adolescent; Adult; Carbamazepine; Chi-Square Distribution; Epilepsy; Fatty Liver; Female; Humans; Ma | 2004 |
Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats.
Topics: Animals; Anticonvulsants; Biomarkers; Dinoprost; Fatty Liver; Glutathione Transferase; Lipid Peroxid | 2005 |
Hepatocellular carcinoma and nonalcoholic steatohepatitis developing during long-term administration of valproic acid.
Topics: Anticonvulsants; Carcinoma, Hepatocellular; Fatty Liver; Hepatitis; Humans; Liver Neoplasms; Male; M | 2005 |
Oxidative stress in experimental liver microvesicular steatosis: role of mitochondria and peroxisomes.
Topics: Animals; Anticholesteremic Agents; Clofibrate; Disease Models, Animal; Enzyme Inhibitors; Fatty Live | 2006 |
Gene expression profiles of murine fatty liver induced by the administration of valproic acid.
Topics: Animals; Anticonvulsants; Fatty Acids; Fatty Liver; Gene Expression Profiling; Lipid Metabolism; Liv | 2007 |
Subchronic effects of valproic acid on gene expression profiles for lipid metabolism in mouse liver.
Topics: Administration, Oral; Animals; Anticonvulsants; Chemical and Drug Induced Liver Injury; Dose-Respons | 2008 |
Toxicity of valproic acid in mice with decreased plasma and tissue carnitine stores.
Topics: Animals; Carnitine; Fatty Liver; Liver; Mice; Mice, Transgenic; Muscle, Skeletal; Tissue Distributio | 2008 |
Drugs and the liver.
Topics: Acetaminophen; Adult; Aspirin; Chemical and Drug Induced Liver Injury; Chemical and Drug Induced Liv | 1984 |
Acute liver disease associated with sodium valproate.
Topics: Acute Disease; Adult; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Epilepsy; Fat | 1980 |
Valproic-acid-associated pancreatitis and hepatic toxicity in children with endstage renal disease.
Topics: Adolescent; Anticonvulsants; Chemical and Drug Induced Liver Injury; Child; Fatal Outcome; Fatty Liv | 1997 |
Re:Incidental microvesicular steatosis due to valproic acid anticonvulsant therapy.
Topics: Fatty Liver; Humans; Valproic Acid | 1992 |
Nodular focal fatty infiltration of the liver in acquired porphyria cutanea tarda.
Topics: Adult; Fatty Liver; Humans; Liver; Male; Porphyrias; Radiography; Skin Diseases; Ultrasonography; Va | 1991 |
Incidental microvesicular steatosis due to valproic acid anticonvulsant therapy.
Topics: Adult; Fatty Liver; Hepatitis C; Hepatitis, Chronic; Humans; Male; Seizures; Valproic Acid | 1991 |